Cctv news(Reporter Kan Chunyu, Lu Yuanyuan): Nine-valent HPV vaccine has been in the public eye for more than three years, but the situation that one vaccine is hard to find is still frequently reported in newspapers, and the vaccine reservation system launched in various places has also received a lot of spit. Why is a nine-valent HPV vaccine hard to find? When will the tight supply situation ease? Qiao Youlin, a professor at the School of Medicine and Public Health of Peking Union Medical College and a member of the expert group on cancer prevention and treatment of WHO Director-General, was interviewed by CCTV reporters.
Qiao Youlin said that at present, the reason why HPV vaccine is hard to find is the imbalance between supply and demand.
Previously, overseas vaccines had to undergo clinical trials in China before entering China, and imported bivalent and tetravalent HPV vaccines had been waiting for 8 years. In 2016, GlaxoSmithKline’s bivalent HPV vaccine sirrah was approved by the State Food and Drug Administration, becoming the first approved HPV vaccine to prevent cervical cancer in China. It was listed overseas in 2006. In 2017, Merck’s tetravalent HPV vaccine was also approved for domestic marketing after 8 years of clinical trials.
However, in 2018, after receiving the application for registration of nine-valent HPV vaccine import, National Medical Products Administration conditionally approved the marketing of Merck’s nine-valent HPV vaccine in just nine days. "Vaccine manufacturers didn’t expect China’s nine-valent vaccine to go on the market within nine days, so its production plan was not arranged at all, and it was suddenly approved. In order to meet the needs of Chinese mainland, they reduced the quotas of other countries to ensure the supply of China, but it was still not enough."
And "the market has accumulated consumer demand for 10 years." In overseas markets, people have gone through a long waiting process from two or four prices to nine prices, but in China, "two or four prices are not popular yet, and nine prices are coming soon, and people want to fight for nine prices, and nine prices are scarce".
Qiao Youlin revealed, "Merck, a nine-valent seedling production company, is also increasing its production capacity and will greatly increase its supply to China next year. There are more than 10 pharmaceutical companies in our country that are making HPV vaccines, so in the next few years, vaccines will continue to be introduced to the market. By that time, vaccines can really cover the whole process, which is not a big problem. "
Qiao Youlin stressed that in the case that there is still a shortage of vaccine supply, it is still necessary to vaccinate the most protected girls under the age of 15 with the best immune effect.
关于作者